Back to Journals » Vascular Health and Risk Management » Volume 10

XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation

Authors Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, van Eickels M, Turpie A

Received 1 March 2014

Accepted for publication 8 May 2014

Published 17 July 2014 Volume 2014:10 Pages 425—434


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

A John Camm,1 Pierre Amarenco,2 Sylvia Haas,3 Susanne Hess,4 Paulus Kirchhof,5,6 Martin van Eickels,4 Alexander GG Turpie7

1Division of Clinical Sciences, St George's, University of London, London, UK; 2Department of Neurology and Stroke Center, Paris-Diderot-Sorbonne University, Paris, France; 3Vascular Center, Munich, Germany; 4Medical Affairs, Bayer HealthCare Pharmaceuticals, Berlin, Germany; 5Centre for Cardiovascular Sciences, University of Birmingham and Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK; 6Department of Cardiovascular Medicine, University of Münster, Münster, Germany; 7Department of Medicine, McMaster University, Hamilton, ON, Canada

Abstract: Atrial fibrillation (AF) is associated with a fivefold increase in the risk of stroke. The Phase III ROCKET AF (Rivaroxaban Once-Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial showed that rivaroxaban, an oral, direct Factor Xa inhibitor, was noninferior to warfarin for the reduction of stroke or systemic embolism in patients with AF. Compared with warfarin, rivaroxaban significantly reduced rates of intracranial and fatal hemorrhages, although not rates of bleeding overall. XANTUS (Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation) is a prospective, international, observational, postauthorization, noninterventional study designed to collect safety and efficacy data on the use of rivaroxaban for stroke prevention in AF in routine clinical practice. The key goal is to determine whether the safety profile of rivaroxaban established in ROCKET AF is also observed in routine clinical practice. XANTUS is designed as a single-arm cohort study to minimize selection bias, and will enroll approximately 6,000 patients (mostly from Europe) with nonvalvular AF prescribed rivaroxaban, irrespective of their level of stroke risk. Overall duration of follow-up will be 1 year; the first patient was enrolled in June 2012. Similar studies (XANTUS-EL [Xarelto® for Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation, Eastern Europe, Middle East, Africa and Latin America] and XANAP [Xarelto® for Prevention of Stroke in Patients with Atrial Fibrillation in Asia-Pacific]) are ongoing in Latin America and Asia-Pacific. Data from these studies will supplement those from ROCKET AF and provide practical information concerning the use of rivaroxaban for stroke prevention in AF.

Keywords: rivaroxaban, anticoagulants, atrial fibrillation, stroke, Phase IV

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]